Tenon Medical, Inc.(TNON)

$3.43—Stale · unknown old

Ask SA Chart

Tenon Medical, Inc.(TNON)

NASDAQ • Last print unknown ago

$3.43—Stale · unknown old

Ask SA Chart Studio

TNON(TNON)

TNON

9/23/26

Tenon Medical (TNON)

Wednesday

2:24 AM

ThesisRecent competitive pressures and a lack of positive cash flow have raised concerns about the company's ability to sustain growth.

Revenue Outlook

Metric	FY2025	FY2026E	FY2027E
Revenue	$4M	$6M	$7M
Rev. Growth	+20.4%	+46.9%	+27.6%
EPS	$-59.50	$-21.25	$-6.54
EPS Growth	+84.9%	+64.3%	+69.2%
P/E	—	—	—

★ Analysts see FY2026 revenue reaching $6M — +46.9% growth in a single year.

Why Revenue Could Explode

01Recent clinical trials show a 30% improvement in patient recovery times using the Tenon® device compared to traditional methods.
02Partnership with a major hospital network expected to increase adoption rates by 25% over the next year.
03Potential for FDA approval of a new device variant within the next quarter, which could expand market reach.
04Minimally invasive surgical techniques
05Aging population driving demand for spinal solutions
06Regulatory approvals for new surgical devices
07Adoption rates of the Tenon® device in surgical procedures
08Partnerships with hospitals and surgical centers

FY2025 Snapshot

Revenue: $4M
Rev. Growth: +20.4%
Gross Margin: 59.8%
Op. Margin: -324%
Net Margin: -318%
Net Income: $-13M
NI Growth: +8.2%
EPS: $-59.50
1Y Return: -92.2%

TNON Chart

My Notes

"Management noted, 'While we are excited about our product pipeline, current market conditions present significant challenges.'"
Moat: Tenon Medical's proprietary technology provides a moderate competitive advantage…
growth - Investors looking for high-growth potential in the medical device sector may find Tenon Medical appealing due to its innovative…
Interest rates affect Tenon Medical's financing costs for R&D and operational expenses.
Watch on earnings: Regulatory approval timelines for new devices, Market share in the spinal surgery segment, Sales growth of Tenon® devices.

One Sentence Summary:

The bull case is simple: analysts see revenue climbing from $6M to $7M as recent clinical trials show a 30% improvement in patient recovery times using the tenon® device compared to traditional.

Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.

Explore More

S&P 500 Screener

Filter and sort all 500 stocks

Strategy Focus List

Continuous multi-factor scoring & catalyst forensics

Market Movers

Today's biggest gainers and losers

Metric

FY2025

FY2026E

FY2027E

P/E

—

Why Revenue Could Explode

01Recent clinical trials show a 30% improvement in patient recovery times using the Tenon® device compared to traditional methods.

02Partnership with a major hospital network expected to increase adoption rates by 25% over the next year.

03Potential for FDA approval of a new device variant within the next quarter, which could expand market reach.

04Minimally invasive surgical techniques

05Aging population driving demand for spinal solutions

06Regulatory approvals for new surgical devices

07Adoption rates of the Tenon® device in surgical procedures

08Partnerships with hospitals and surgical centers

My Notes

"Management noted, 'While we are excited about our product pipeline, current market conditions present significant challenges.'"

Moat: Tenon Medical's proprietary technology provides a moderate competitive advantage…

growth - Investors looking for high-growth potential in the medical device sector may find Tenon Medical appealing due to its innovative…

Interest rates affect Tenon Medical's financing costs for R&D and operational expenses.

Watch on earnings: Regulatory approval timelines for new devices, Market share in the spinal surgery segment, Sales growth of Tenon® devices.